RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Sponsor: Boehringer Ingelheim
This observational or N/A phase trial investigates Venous Thromboembolism and is currently completed. Boehringer Ingelheim leads this study, which shows 21 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
21 versions recorded-
Nov 2025 — Present [monthly]
Completed
-
Sep 2025 — Nov 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
▶ Show 16 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed
-
May 2019 — May 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting
-
Oct 2018 — Dec 2018 [monthly]
Active Not Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting
-
Jul 2018 — Sep 2018 [monthly]
Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Recruiting NA
-
Sep 2017 — Dec 2017 [monthly]
Recruiting NA
-
Aug 2017 — Sep 2017 [monthly]
Recruiting NA
-
Jun 2017 — Aug 2017 [monthly]
Recruiting NA
-
May 2017 — Jun 2017 [monthly]
Recruiting NA
-
Mar 2017 — May 2017 [monthly]
Recruiting NA
-
Jan 2017 — Mar 2017 [monthly]
Recruiting NA
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Acerra, Italy , Alba, Italy , Alexandria, Egypt , Alexandroupoli, Greece , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Anyang-si, South Korea , Armenia, Colombia , Athens, Greece , Atlanta, United States and 164 more locations